Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Pancreatic Neoplasms 42Urinary Bladder Neoplasms 18Carcinoma, Non-Small-Cell Lung 18Ovarian Neoplasms 11Triple Negative Breast Neoplasms 10Neoplasm Metastasis 10Nasopharyngeal Carcinoma 10Breast Neoplasms 10Lymphoma, Large B-Cell, Diffuse 9Fallopian Tube Neoplasms 9Lung Neoplasms 8Carcinoma, Transitional Cell 8Biliary Tract Neoplasms 7Recurrence 6Gallbladder Neoplasms 6Neoplasms 5Cholangiocarcinoma 5Non-Muscle Invasive Bladder Neoplasms 4Colorectal Neoplasms 4Urothelial Cancer 3Stomach Neoplasms 3Melanoma 3Lymphoma, Non-Hodgkin 3Lymphoma 3Carcinoma 3Uterine Cervical Neoplasms 2Urethral Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic Adenocarcinoma 2Non Small Cell Lung Carcinoma NSCLC 2

Interventions

Vincristine 2Radiotherapy 2Cyclophosphamide 2Cisplatin 2Pemetrexed 1Maintenance Chemotherapy 1Lomustine 1Induction Chemotherapy 1HhAntag691 1Gemcitabine 1Exercise 1Diploidy 1Craniospinal Irradiation 1Carboplatin 1CLR1404 1Automobiles 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neuroectodermal Tumors, Primitive × Gemcitabine × Clear all
NCT01878617 2025-11-13

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
660 enrolled
CNS

Brain Neoplasms, Medulloblastoma, Infratentorial Neoplasms, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡